Friday, May 2nd, 2025

ClearBridge Health Secures SGX-ST Approval for 309.5 Million Share Placement








Clearbridge Health’s Bold Move: 309.5 Million New Shares Approved for Listing

Clearbridge Health’s Bold Move: 309.5 Million New Shares Approved for Listing

Clearbridge Health Limited, a key player in Singapore’s healthcare sector, has announced a significant development that could have major implications for its shareholders and potential investors. The company has received an in-principle approval from the Singapore Exchange Securities Trading Limited (SGX-ST) for the listing and quotation of 309,500,000 new ordinary shares on the Catalist board. This announcement follows the company’s earlier disclosure on December 19, 2024, regarding its proposed placement of these shares.

Key Highlights from the Announcement

  • Approval Secured: As of January 8, 2025, Clearbridge Health has obtained the Listing and Quotation Notice (LQN) from SGX-ST for the Proposed Placement of 309.5 million new shares.
  • Placement Deadline: The Subscription Shares must be placed out within seven market days from the LQN’s date.
  • Conditional Approval: The LQN is contingent on the company’s compliance with SGX-ST’s listing requirements.
  • No Merits Assessed: SGX-ST’s approval does not reflect the merits of the Proposed Placement, the Subscription Shares, or the company and its securities.

What Shareholders Need to Know

For shareholders and potential investors, this development can be significant for several reasons:

  • The issuance of 309.5 million new shares represents a substantial increase in the company’s share capital, which could lead to dilution for existing shareholders.
  • The capital raised from this placement, depending on its utilization, could strengthen Clearbridge Health’s financial position and fuel growth initiatives.
  • The company has committed to keeping shareholders informed about material developments regarding the Proposed Placement.

However, shareholders are urged to exercise caution when dealing in the company’s securities, as the LQN does not guarantee the success of the Proposed Placement or its impact on the company’s financial health and stock value. Any uncertainties or missteps in execution might affect investor confidence and share prices.

Next Steps

Clearbridge Health has pledged to release updates and announcements as appropriate to keep its shareholders informed about the Proposed Placement’s progress. Investors are advised to monitor these updates closely and consult professional advisers if needed.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. Shareholders and potential investors are strongly encouraged to conduct their own research or consult with professional advisers before making any investment decisions related to Clearbridge Health Limited.




View Clearbridge Historical chart here



Keppel DC REIT Raises S$1.1 Billion in Oversubscribed Equity Fund Raising

Keppel DC REIT’s S\$1.1 Billion Equity Fund Raising: A Strategic Move for Growth Keppel DC REIT’s S\$1.1 Billion Equity Fund Raising: A Strategic Move for Growth Keppel DC REIT Management Pte. Ltd. has announced...

Courage Investment Group Limited Annual Report 2024: Financial Performance and ESG Initiatives

Courage Investment Group Limited Reports Increased Revenue and Profit in 2024 Courage Investment Group Limited (HK Stock Code: 1145) (SGX-ST: CIN) released its annual report for 2024, highlighting a significant increase in revenue and...

Rex International Updates FY2024 Financial Loss Allocation: Key Revisions Explained

Rex International’s FY2024 Addendum: Reshuffled Loss Allocation Sparks Shareholder Spotlight Rex International’s FY2024 Addendum: Reshuffled Loss Allocation Sparks Shareholder Spotlight Rex International Holding Limited has issued an important addendum to its FY2024 Condensed Interim...